Passion for Innovation. Compassion for Patients.™

Daiichi Sankyo Europe GmbH

European News

Daiichi Sankyo Partners With World Thrombosis Day

Promoting awareness of venous thromboembolism and atrial fibrillation, helping to reduce preventable deaths

Expert report highlights urgent action needed to lessen the future impact of Atrial Fibrillation in Europe

Report[1] recommendations aim to improve management of AF as numbers expected to double from 8.8 to 17.9 million adults aged over 55 years between…

Lixiana® (edoxaban) Approved in Switzerland

Daiichi Sankyo’s Once-Daily Lixiana® (edoxaban) Approved for the Prevention of Stroke and Systemic Embolism in Non-Valvular Atrial Fibrillation and…